Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.
about
Aminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes for chronic hepatitis CAminoadamantanes versus other antiviral drugs for chronic hepatitis CPeginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CExtended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patientsAminoadamantanes for chronic hepatitis CChronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysisEfficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysisUltrasensitive HCV RNA Quantification in Antiviral Triple Therapy: New Insight on Viral Clearance Dynamics and Treatment Outcome PredictorsPandemic H1N1 influenza.Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responseThe hepatitis C virus NS5A inhibitor daclatasvir has a dual mode of action and leads to a new virus half-life estimateThyroid disease is a favorable prognostic factor in achieving sustained virologic response in chronic hepatitis C undergoing combination therapy: A nested case control study.Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis.Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelMeta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C.Evolution of interferon-based therapy for chronic hepatitis C.Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C.Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis.Peginterferon and ribavirin treatment for hepatitis C virus infectionModelling heterogeneity variances in multiple treatment comparison meta-analysis--are informative priors the better solution?Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population.Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled TrialsA perspective on modelling hepatitis C virus infection.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Production of a particulate hepatitis C vaccine candidate by an engineered Lactococcus lactis strain.Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin.Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)Understanding silibinin's modes of action against HCV using viral kinetic modelingEfficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C.Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective StudyPegylated interferon alfa and ribavirin for children with chronic hepatitis CMathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis CWhat the infectious disease physician needs to know about pegylated interferon and ribavirin.
P2860
Q24193940-B7BEDFF1-8308-4F55-A6E7-E2D79DB47F2AQ24194770-64A78739-1E15-43D4-BD95-3F5B155317DEQ24194815-63DD8810-5C85-4571-A52D-3F3C0A169C5DQ24200197-9DBE1197-3E5F-4EF4-9FD4-C49F67645F6DQ24200534-FDF82A77-E237-406D-8CC9-C2AFE46DEE58Q24201226-5760EE24-96CC-4544-8C8D-0A7FBE894647Q26991791-6F3E8E4F-F053-4978-8450-4CB9B0BDF52AQ28281519-05C53952-1D82-4975-9615-6DBAC751972EQ28553721-CCD886CC-8214-4BD5-A1C1-9630121DB7EEQ30412025-72C14664-600D-4125-BB47-7BAB1E0B04C3Q33419636-BA9A7E12-296F-4214-9A6E-D7593BD9B54AQ33559298-15A9904B-10CD-45F9-BF64-96DF81485FDCQ33769085-195DEFF2-87EE-4C0E-B235-97507481A69BQ33794371-B259A843-7074-4DCD-8900-B629E1859557Q33909535-518B7386-A091-48FD-9A91-C116E8831DB9Q34329513-CD98A3F1-D7E0-4828-A3F7-736AD1D8D316Q34334375-7BFF8235-F264-4048-932F-8078FACC54A6Q34334776-695D2F97-571B-4BDF-AF92-76558F1F977BQ34342092-76F6F959-5C5C-4DD2-BA54-B63DBC1AE242Q34365442-CF96501D-7B9C-4AED-BADC-5F237E522793Q34514292-45CC8596-3D3E-4DC8-8894-9DF88E2028BBQ34521371-DD51FC3C-0FB8-41DA-8F8B-BBD5382D2637Q34545549-243333B1-07BC-441F-AFAD-835E2ACCF3F0Q34626479-9F4D8BA1-E8DE-449D-9062-FB9A37471280Q34694441-78EC27DD-01A1-47F5-BFE2-5E4CA786189EQ34714220-36C8CDAC-ED22-475C-81A9-40972417AAF1Q34759489-61E4A84E-08B7-448F-A549-5C840F1EFC55Q35205389-287BAC62-0A3E-4076-842E-FB4191161ECDQ35599219-F9E42E96-D2FD-4638-BEC3-A8768806366BQ35736293-70542E22-58EE-4039-9E30-A3112B09DA68Q35833191-70E0180D-FF1F-448E-9193-3A32A32948E9Q35839723-6F62688A-2BE3-4080-B034-6ECAA8C44372Q35878898-CF158526-AB77-4044-A68C-2116A86FC17BQ35894929-9C8B3AB5-D207-4342-AE43-66596260497DQ36182539-4107A731-5B29-430A-A344-F932DA97E61FQ36618416-EBA516CA-38BD-49CE-8FBF-595C749D8F9CQ36637715-78951E09-C60D-4AFA-A6F6-517B86F05A0CQ36810400-D5393B60-879D-4986-823E-B6BC9AF32F06Q36810865-62C4EAD6-35BE-4AC8-8C6E-B04F97C29A21Q36811232-71F0B95B-D61B-4CB0-8579-D8CB4073C998
P2860
Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@ast
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@en
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@nl
type
label
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@ast
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@en
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@nl
prefLabel
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@ast
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@en
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@nl
P2860
P50
P356
P1433
P1476
Peginterferon alpha-2a is asso ...... c review of randomized trials.
@en
P2093
Kristian Thorlund
Mahasen Mabrouk
P2860
P304
P356
10.1002/HEP.23504
P407
P577
2010-04-01T00:00:00Z